Headlines about Cepheid (NASDAQ:CPHD) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cepheid earned a daily sentiment score of 0.03 on Accern’s scale. Accern also gave media headlines about the scientific and technical instruments company an impact score of 51.7228357692137 out of 100, indicating that recent press coverage is somewhat likely to have an effect on the company’s share price in the immediate future.
Cepheid (NASDAQ:CPHD) remained flat at $52.95 during trading on Wednesday. Cepheid has a 1-year low of $25.09 and a 1-year high of $53.91. The firm’s 50 day moving average price is $52.75 and its 200 day moving average price is $38.36.
ILLEGAL ACTIVITY WARNING: This article was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://www.chaffeybreeze.com/2017/09/20/cepheid-cphd-given-daily-media-impact-rating-of-0-03.html.
Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company’s systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures.
Receive News & Ratings for Cepheid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cepheid and related companies with MarketBeat.com's FREE daily email newsletter.